FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma

Journal of Nuclear Medicine

Volumn 40, Issue 9, 1999, Pages 1407-1413

  Moog, Florian ^a,b   Kotzerke, Jörg ^a   Reske, Sven N ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

18F fluorodeoxyglucose PET; Bone scintigraphy; Lymphoma; Skeletal involvement; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER SCINTISCANNING; CANCER STAGING; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; BIOPSY; BONE AND BONES; BONE MARROW; BONE NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032845962     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Guillemart A, Besnard JC, Pape AL, et al. Skeletal uptake of pyrophosphate labeled with technetium-95m and technetium-96, as evaluated by autoradiography. J Nucl Med. 1978;19:895-899.
2. Wilson AW. Musculoskeletal system. In: Wilson MA, ed. Textbook of Nuclear Medicine. Philadelphia, PA: Lippincott-Raven Publishers; 1998:3-32.
3. Orzel J, Sawaf NW, Richardson ML. Lymphoma of the skeleton: scintigraphic evaluation. Am J Rehabil. 1988;150:1095-1099.
4. Schechter JP, Jones SE, Woolfenden JM, et al. Bone scanning in lymphoma. Cancer. 1976;38:1142-1146.
5. Ferrant A, Rodhain J, Michaux JL, Piret L, Maldague B, Sokal G. Detection of skeletal involvement in Hodgkin's disease: a comparison of radiography, bone scanning, and bone marrow biopsy in 38 patients. Cancer. 1975;35:1345-1353.
6. Malloy PC, Fishman EK, Magid D. Lymphoma of bone, muscle, and skin: CT findings. Am J Rehabil. 1992;159:805-809.
7. Edeiken-Monroe B, Edeiken J, Kim E. Radiologic concepts of lymphoma of bone. Radiol Clin North Am. 1990;28:841-864.
8. Jânoskuti L, Szilvôsi I, Papp G, Rona E, Benedek S, Fekete S. Bone scanning and radiography in the evaluation of patients with malignant lymphoma. Fortschr Röntgenstr. 1988;149:427-428.
9. Edelstyn GA, Gillespie PJ, Grebbbell FS. The radiological demonstration of osseous metastasis. Experimental observations. Clin Radiol. 1967;18:158-162.
10. Moon TY, Kim EE, Kim YC, et al. Comparison of nuclear bone and gallium scans in the therapeutic evaluation of bone lymphoma. Clin Nucl Med. 1995;20:721-724.
11. Bar-Shalom R, Israel O, Epelbaum R, et al. Gallium-67 scintigraphy in lymphoma with bone involvement. J Nucl Med. 1995;36:446-450.
12. 67Ga scintigraphy in the initial diagnosis of bone involvement in children with malignant lymphoma. Nucl Med Commun. 1994;15:144-147.
13. Kern KA, Brunetti A, Norton JA, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med. 1988;29:181-188.
14. Adler LP, Blair HF, Makley JT, et al. Non-invasive grading of musculoskeletal tumors using PET. J Nucl Med. 1991;32:1508-1512.
15. Dehdashti F, Siegel BA, Griffeth LK, et al. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose. Radiology. 1996;200:243-247.
16. Wahl RL, Cody RL, Hutchins GD, et al. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with radiolabeled glucose analogue 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology. 1991;179:765-770.
17. Shreve PD, Grossman HB, Gross MD, et al. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-(F-18)fluoro-D-glucose. Radiology. 1996;199:751-756.
18. Sasaki M, Ichiya Y, Kuwabara Y, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in technetium-99m-hydroxymethylenediphosphate negative bone tumors. J Nucl Med. 1992;34:288-290.
19. Newman JS, Francis IR, Kaminski MS, et al. Imaging of lymphoma with PET with 2-(F-18)-fluoro-2-deoxy-d-glucose: correlation with CT. Radiology. 1994;190: 111-116.
20. Moog F, Bangerter M, Diederichs C, et al. Lymphoma: role of whole-body FDG-PET in nodal staging. Radiology. 1997;203:795-800.
21. Moog F, Bangerter M, Diederichs C, et al. Malignant lymphoma: detection with F-18-FDG PET versus CT. Radiology. 1998;206:475-481.
22. Moog F, Bangerter M, Kotzerke J, et al. FDG PET as a new approach to detect lymphomatous bone marrow. J Clin Oncol. 1998;16:603-609.
23. Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med. 1997;38:343-348.
24. Stansfeld AG. Updated Kiel Classification for lymphomas. Lancet. 1988;6:292-293.
25. 18F)-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1987;27:235-238.
26. Schmidlin P. Improved iterative image reconstruction using variable projection binning and abbreviated convolution. Eur J Nucl Med. 1994;21:930-936.
27. Harder J. Knochengranulomatose. Fortschr Röntgenstr. 1960;63:445-450.
28. Vieta JO, Friedell HL, Craver LF. A survey of Hodgkin's disease and lymphosarcoma in bone. Radiology. 1942;39:1-15.
29. Braunstein EM, While SJ. Non-Hodgkin lymphoma of bone. Radiology. 1980;135: 59-63.
30. Munker R, Hasenclever D, Brosteanu O, et al. Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. J Clin Oncol. 1995;13: 403-409.
31. Ellis ME, Diehl LF, Granger E, et al. Trephine needle bone marrow biopsy in the initial staging of Hodgkin's disease: sensitivity and specificity of the Ann Arbor staging procedure criteria. Am J Hematol. 1989;30:115-120.
32. Tsunoda S, Takagi S, Tanaka O, Miura Y. Clinical and prognostic significance of femoral marrow magnetic resonance imaging in patients with malignant lymphoma. Blood. 1997;89:286-290.
33. Reske SN, Karstens JH, Gloeckner W, et al. Radioimmunoimaging for diagnosis of bone marrow involvement in breast cancer and malignant lymphoma. Lancet. 1989;2:299-301.
34. Zasadny K, Wahl RL. Standardized uptake values of normal tissues at PET with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology. 1993;189:847-850.
35. Lapela M, Leskinen S, Minn H, et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood. 1995;9:3522-3527.
36. Kotzerke J, Guhlmann A, Moog F, et al. Role of attenuation correction for FDG-PET in the primary staging of malignant lymphoma. Eur J Nucl Med. 1999;26:31-38.
37. Hoffman JM, Waskin HA, Hanson MW, et al. FDG PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med. 1993;34:567-575.